Obtained three ISO certifications under the Integrated Management System:
– ISO 9001:2015
– ISO 15189:2014
– ISO 18025:2017
The Group gets affected issuer status uplifted, Bursa Securities waives need for Group to submit
Acquired 51% of Aquahealth Sdn Bhd to pioneer renal care via Rinani Renal Berhad.
Established centralised facility housing a new genomics laboratory, a biosafety level 2 cell laboratory, and the company’s headquarters.
Partnered with Pharmaniaga Lifesciences Sdn Bhd on the distribution of COVID-19 vaccines around Malaysia.
Diversification into CAR T-cell immunotherapy for cancers.
Divested MPath Sdn Bhd to unlock the value of the investment into pathology.
Acquired remaining 50% of Clinipath Pathology via MPath Sdn Bhd.
Diversified into clinical pathology services by acquiring 50% of Clinipath Pathology via MPath Sdn Bhd.
Launched Dtect® genetic screening tests (14 different genetic screening profiles today).
Listed on the ACE Market of Bursa Malaysia Securities Berhad.
Completed the world’s largest genome assembly of the oil palm genome.
Commenced contract genomics research services for international customers including Brigham & Women’s Hospital (the teaching affiliate of Harvard Medical School), Novartis, AstraZeneca, Pure Circle, April Pulp & Paper, etc.
Incorporated Malaysian Genomics Resource Centre Berhad.
Malaysian Genomics Resource Centre Berhad has successfully obtained three ISO certifications under the Integrated Management System.